Loading
Nivolumab lengthened survival compared with standard single-agent chemotherapy in head and neck cancer that had progressed within six months of platinum treatment, the first immunotherapy to improve survival in the disease.
Phase 3 trial of 361 patients with recurrent or metastatic head and neck squamous cell carcinoma progressing within six months of platinum-based therapy, randomised 2:1 to nivolumab or investigator's choice of methotrexate, docetaxel or cetuximab.
Median overall survival was 7.5 versus 5.1 months (hazard ratio 0.70) and one-year survival 36.0 versus 16.6 percent, with fewer grade 3 to 4 adverse events (13.1 versus 35.1 percent) and better quality of life.
PD-1 blockade after platinum became standard, and the trial opened the way for first-line pembrolizumab in KEYNOTE-048.
Shares Oropharyngeal cancer (tonsil and base of tongue), New England Journal of Medicine.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, New England Journal of Medicine.
Shares Oropharyngeal cancer (tonsil and base of tongue), Recurrent or metastatic head and neck squamous cell carcinoma.
Shares CheckMate 141, Nivolumab.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Nivolumab.
Shares Oropharyngeal cancer (tonsil and base of tongue), Recurrent or metastatic head and neck squamous cell carcinoma.
Shares Robert L. Ferris, Oropharyngeal cancer (tonsil and base of tongue), Recurrent or metastatic head and neck squamous cell carcinoma.
Shares Oropharyngeal cancer (tonsil and base of tongue), Recurrent or metastatic head and neck squamous cell carcinoma.